Heron Therapeutics (NASDAQ:HRTX) Posts Earnings Results, Beats Expectations By $0.02 EPS

Heron Therapeutics (NASDAQ:HRTX - Get Free Report) released its quarterly earnings data on Tuesday. The biotechnology company reported $0.01 EPS for the quarter, beating analysts' consensus estimates of ($0.01) by $0.02, Zacks reports. The company had revenue of $38.90 million during the quarter, compared to the consensus estimate of $37.08 million. Heron Therapeutics updated its FY 2025 guidance to EPS.

Heron Therapeutics Price Performance

Shares of NASDAQ:HRTX opened at $2.42 on Wednesday. The company's 50-day moving average price is $2.20 and its two-hundred day moving average price is $1.81. Heron Therapeutics has a one year low of $1.04 and a one year high of $3.93. The stock has a market capitalization of $369.13 million, a PE ratio of -13.44 and a beta of 1.33.

Wall Street Analyst Weigh In

HRTX has been the subject of several analyst reports. StockNews.com lowered Heron Therapeutics from a "buy" rating to a "hold" rating in a research report on Saturday, March 8th. Needham & Company LLC reaffirmed a "buy" rating and issued a $4.00 target price on shares of Heron Therapeutics in a research note on Friday, April 11th.

Heron Therapeutics Company Profile

Heron Therapeutics, Inc, a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.